Company: MLTX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001821586-25-000022
Chunk: 100

Company: MoonLake Immunotherapeutics
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 100
---
000841,269600,000,00063,918,700Conversion of Class C Ordinary Shares into Class A Ordinary Shares—111,949—(111,949)——Option exercised and converted under the Employee Stock Option Plan—93,347———93,347Issuance of Restricted Stock Awards under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan—191,526———191,526Balance at March 31, 2025500,000,00063,474,253100,000,000729,320600,000,00064,203,573Balance at June 30, 2025500,000,00063,474,253100,000,000729,320600,000,00064,203,573Conversion of Class C Ordinary Shares into Class A Ordinary Shares—203,142—(203,142)——Options exercised under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan Equity Incentive Plan—27,149———27,149Balance at September 30, 2025500,000,00063,704,544100,000,000526,178600,000,00064,230,722(1) Fully paid-in registered shares with a par value of $0.0001 Class A Ordinary SharesOn April 6, 2022, the Company's Class A Ordinary Shares began trading on The Nasdaq Capital Market ("Nasdaq") under the symbol “MLTX”. As of September 30, 2025, there were 63,704,544 Class A Ordinary Shares issued and outstanding. The Company is authorized to issue up to 500,000,000 Class A Ordinary Shares, par value $0.0001 per share. Holders of Class A Ordinary Shares are entitled to one vote per share. Class C Ordinary SharesAs of September 30, 2025, there were 526,178 Class C Ordinary Shares issued and outstanding. The Company is authorized to issue up to 100,000,000 Class C Ordinary Shares, with a par value $0.0001 per share. Each Class C Ordinary Share entitles the holders thereof to one vote per share, but carries no economic rights.

22

MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2025(Unaudited)

At the closing of the Business Combination, MoonLake, MoonLake